Get started
Author

Meera Raymond

ORCID: 0009-0007-6611-0914
Observed ORCID: 0009-0007-6611-0914
OpenAlex ID: A5140797906
Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma
2023 · Claire Roddie, Lazaros J. Lekakis, et al. · Blood · 74
PDF
Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf
2012 · Tizong Miao, Meera Raymond, et al. · The Journal of Immunology · 64
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial
2024 · Kate Cwynarski, Gloria Iacoboni, et al. · Nature Medicine · 47
IL-1β stimulation of CCD-18co myofibroblasts enhances repair of epithelial monolayers through Wnt-5a
2012 · Meera Raymond, Tania Marchbank, et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 9
Long-Term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ([R/R B-ALL]; Pooled Analysis from ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study)
2023 · Claire Roddie, Eleni Tholouli, et al. · Blood · 5
Immune reconstitution following umbilical cord blood transplantation: IRES, a study of UK paediatric patients
2020 · John Girdlestone, Meera Raymond, et al. · eJHaem · 4
PDF
ALL-502 Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden–Guided Dosing in the FELIX Phase 1b/2 Study
2024 · Elias Jabbour, Karamjeet S. Sandhu, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Figure 2 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 5 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S5 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Data from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Figure S1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S6 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S2 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 4 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S4 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Table 1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al. · Cancer Research Communications
Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden–Guided Dosing in the FELIX Phase 1b/2 Study
2024 · Elias Jabbour, Karamjeet S. Sandhu, et al. · Clinical Lymphoma Myeloma & Leukemia
S262: Safety and Efficacy of Obecabtagene Autoleucel (obe-cel), a Fast-off Rate Cd19 Car in Relapsed/refractory Adult B-cell Acute Lymphoblastic Leukaemia:top Line Results of the Pivotal Felix Study
2023 · Claire Roddie, Karamjeet Sandhu, et al. · HemaSphere
Egr-2 regulates inflammatory plasticity of effector T cells (167.1)
2011 · Meera Raymond, Ping Wang · The Journal of Immunology
Works count: 25
Citation count: 203
H-index: 5
I10-index: 3
Year
Topic
Type